AIRLINK 86.21 Decreased By ▼ -0.99 (-1.14%)
BOP 4.97 Decreased By ▼ -0.05 (-1%)
CNERGY 4.08 Decreased By ▼ -0.01 (-0.24%)
DFML 37.22 Decreased By ▼ -0.68 (-1.79%)
DGKC 91.20 Decreased By ▼ -2.68 (-2.85%)
FCCL 22.99 Decreased By ▼ -0.78 (-3.28%)
FFBL 33.74 Increased By ▲ 1.07 (3.28%)
FFL 9.19 Decreased By ▼ -0.06 (-0.65%)
GGL 10.05 Increased By ▲ 0.02 (0.2%)
HASCOL 6.25 Decreased By ▼ -0.29 (-4.43%)
HBL 126.25 Increased By ▲ 4.33 (3.55%)
HUBC 158.29 Increased By ▲ 12.64 (8.68%)
HUMNL 11.08 Increased By ▲ 0.58 (5.52%)
KEL 4.64 Decreased By ▼ -0.10 (-2.11%)
KOSM 4.09 Decreased By ▼ -0.10 (-2.39%)
MLCF 38.25 Decreased By ▼ -0.55 (-1.42%)
OGDC 133.40 Decreased By ▼ -1.61 (-1.19%)
PAEL 25.40 Increased By ▲ 0.32 (1.28%)
PIBTL 6.22 Decreased By ▼ -0.05 (-0.8%)
PPL 119.25 Decreased By ▼ -0.43 (-0.36%)
PRL 24.58 Increased By ▲ 0.48 (1.99%)
PTC 12.28 Increased By ▲ 0.06 (0.49%)
SEARL 59.32 Decreased By ▼ -0.48 (-0.8%)
SNGP 65.60 Increased By ▲ 0.60 (0.92%)
SSGC 9.87 Decreased By ▼ -0.18 (-1.79%)
TELE 7.85 Decreased By ▼ -0.02 (-0.25%)
TPLP 9.49 Decreased By ▼ -0.25 (-2.57%)
TRG 63.80 Decreased By ▼ -0.50 (-0.78%)
UNITY 27.26 Increased By ▲ 0.21 (0.78%)
WTL 1.28 Decreased By ▼ -0.04 (-3.03%)
BR100 8,343 Increased By 33.1 (0.4%)
BR30 26,460 Increased By 509.8 (1.96%)
KSE100 78,810 Increased By 9 (0.01%)
KSE30 25,474 Increased By 35.6 (0.14%)
Pakistan

Pakistan has not placed any orders for the coronavirus vaccine yet: Report

  • Top federal government health authorities have confirmed that Pakistan has neither placed any final order yet to acquire the COVID-19 vaccine nor has any vaccine manufacturer accepted the country’s request for supply of the vaccine.
  • Health authorities in Pakistan are aiming to vaccinate around 100 million of its adult population or at least 70-80 million people.
Published January 15, 2021

KARACHI: Amidst speculations about coronavirus trials in Pakistan, federal government health authorities have confirmed that Pakistan has neither placed any final order to acquire the COVID-19 vaccine, nor has any vaccine manufacturer accepted the country’s request as of yet.

As reported by The News on Friday, Special Assistant to Prime Minister on Health Dr Faisal Sultan stated that "Although, we are striving hard to get the first batch of COVID-19 vaccine at the earliest for our frontline workers and others the final order has not yet been placed and accepted [by any vaccine manufacturer]".

He mentioned that as of yet, China's Sinopharm has submitted its data with Pakistan's Drug Regulatory Authority (DRAP), and the health authorities are engaged in negotiations for the supply of vaccines, but there has been no agreement with them currently.

“The second vaccine candidate is Cansino, whose trials are currently underway and they are a couple of weeks away from submitting their data to us. We are also interested in Russian vaccine Sputnik V, who have submitted some data but we have sought more data from them,” Sultan informed.

Shedding light upon the acquisition of Western-produced vaccines, the health official stated that negotiations are underway with AstraZeneca’s manufacturer, adding that "We are trying to get AstraZeneca vaccine both through the Covax facility and through direct procurement".

Health authorities in Pakistan are aiming to vaccinate around 100 million of its adult population, or at least 70-80 million people, a procedure that will take time and a "mix-and-match" approach to vaccine the targeted population.

The authorities stated that the Chinese vaccine was only found to be 50.4% effective in Brazilian clinical trials which shows that more data is required as using a 50% effective vaccine would be a total waste of efforts and resources.

“We need to assess the data of the vaccine’s efficacy ourselves before selecting it for the population. We would prefer a vaccine which has an emergency use authorization either from US FDA, European authorities or the World Health Organisation or its data shows at least 80-90 percent efficacy and safety,” according to a DRAP official.

Comments

Comments are closed.